Patterns Of Hedgehog Inhibitor (HHI) Treatment Interruptions and Reinitiations Among Patients with Basal Cell Carcinoma (BCC) in Real-World Clinical Practice

Main Article Content

Jessica Jalbert
Chieh-I Chen
Ning Wu
Matthew Fury
Wenzhen Ge
Emily Ruiz


Skin Cancer, Basal cell Carcinoma, Hedgehog Inhibitor, Real-World


Abstract not available.


1. Migden MR et al. Cancer Treat Rev. 2018;64:1–10.

2. Lear JT et al. Br J Cancer. 2014;111:1476–1481.

3. Kudchadkar R et al. Semin Oncol. 2012;39:139–144.

4. American Cancer Society. Treating basal cell carcinoma; 2019. Available at: [Accessed July 24, 2020].

5. Trakatelli M et al. Eur J Dermatol. 2014;24:312–329.

6. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: basal cell skin cancer version 1.2020; 2019. Available at: [Accessed June 2, 2020].

7. Cancer Council Australia/Australian Cancer Network. Basal cell carcinoma, squamous cell carcinoma (and related lesions) – a guide to clinical management in Australia; 2008; 2008. Available at: [Accessed July 24, 2020].

8. Goldenberg G et al. J Am Acad Dermatol. 2016;75:957–966.

9. Sekulic A et al. J Am Acad Dermatol. 2015;72:1021–1026 e1028.

10. Basset-Seguin N et al. Eur J Cancer. 2017;86:334–348.

Most read articles by the same author(s)